Pricing Log in Create free account
Friday 6 November 2026 Export COR’s income statement to Excel — free account

Cencora, Inc.

COR Healthcare Medical Distribution

Cencora, Inc.’s revenue for fiscal 2026 (year ended September 2026) was $337.4 billion, up 5.00% from fiscal 2025.

Revenue
+5.52%
EPS
+258.4%
Free cash flow
−7.81%
Total debt
+47.1%

Quarter to September 2026, against a year earlier

334.21 5.47 −1.61%
Market cap
$64.8B
P/E
18.8×
Fwd P/E
17.5×
Dividend yield
0.71%
F-score
7/9
Altman Z
n/a
Beneish M
−2.59
Dividend safety
70/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cencora, Inc. 10-Q filed May 6, 2026

Fiscal Q2 2026 · Period ended Mar 31, 2026 · Filed · accepted 2:41 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Feb 4, 2026: 18 added · 8 removed · 52 modified; 15 with only figures updated

  1. Removed · New Reporting Structure

    We undertook a strategic review of our business to ensure alignment with our growth priorities and strategic drivers. As a result of this review, beginning in the first quarter of fiscal 2026, we reorganized certain business components within our reporting structure. Our revised reporting structure is comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment consists of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment consists of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, consists of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of PharmaLex. Our previously reported segment results have been revised to conform to our re-aligned reporting structure.